The city of Boston, Massachusetts, currently has 480 active clinical trials seeking participants for Cancer research studies.
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT04443348
Recruiting
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: * Radiation Therapy (RT) * Immunotherapy: Pembrolizumab (MK-3475) * Chemotherapies: * Paclitaxel * Doxorubicin (also called Adriamycin) * Cyclophosphamide * Carboplatin (optional, and in TN onl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Register for Updates
Immune and Genomic Markers in ALK+ NSCLC
NCT04881916
Recruiting
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Anaplastic Lymphoma Kinase Gene Translocation, Non-Small Cell Lung Cancer
Register for Updates
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423
Recruiting
The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor. The names of the study interventions involved in this study are: * Cryoablation (an interventional radiology procedure that freezes part of a tumor) * Ipilimumab (an immunotherapy) * Nivolumab (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
NCT06146920
Recruiting
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma, Non-small Cell Lung Cancer
Register for Updates
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
NCT05524428
Recruiting
The investigators will use a mixed methods study i.e. focus groups involving CHC staff as well as quantitative study which involves analyzing data that is available from the EHR and DRVS population management platform.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Codman Square Health Center, Boston, Massachusetts
Conditions: Colo-rectal Cancer
Register for Updates
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
NCT04305145
Recruiting
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: * How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? * How many patients treated with steroids experience steroid-free disease resolution after 7 weeks?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
Register for Updates
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
NCT04430699
Recruiting
This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: * Cisplatin (standard of care drug) * Pembrolizumab (investigational drug) * Radiation Therapy (standard of care intervention)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Vulvar Cancer, Vulvar Squamous Cell Carcinoma
Register for Updates
Multimodal Machine Learning Characterization of Solid Tumors
NCT04687969
Recruiting
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma, Prostate Cancer, Renal Cell Carcinoma (RCC)
Register for Updates
MRI Guided Prostate Biopsy
NCT06302595
Recruiting
This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy. The feasibility in this study is defined as whether the needle holder frame enables accurate tissue sampling from a suspicious region in the prostate found on an MR image. If it does, a biopsy can be carried out with the needle holder frame safely in a clinical routine. The study will be conducted during a rou... Read More
Gender:
MALE
Ages:
30 years and above
Trial Updated:
03/08/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Suspected Prostate Cancer
Register for Updates
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
NCT04634357
Recruiting
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
03/05/2024
Locations: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
Conditions: Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS
Register for Updates
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
NCT03854110
Recruiting
This is a phase 1 first in human, dose escalation trial of GP-2250 administered in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy. Prior radiosensitization with gemcitabine, the use of 5-fluorouracil, FOLFIRINOX or Nab-paclitaxel/gemcitabine in the neoadjuvant setting, and prior pancreaticoduodenectomy (Whipple procedure) is allowed. If prior treatment with gemcitabine was at therapeutic doses, a minimum of 3 mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Pancreatic Cancer, Adult
Register for Updates
Amivantamab in Adenoid Cystic Carcinoma
NCT05074940
Recruiting
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Salivary Gland Cancer
Register for Updates